NTLX:TSXV, NeuroThera Labs Inc.
NTLX stock overview
NeuroThera Labs Inc. (NTLX:TSXV) closed at $1.67 on October 16, 2026,
down 27.39% on the day.
It is trading at its 52-week low of $1.67.
NeuroThera Labs Inc. is part of the Health Care sector.
Key figures
- Price
- $1.67
- Day change
- -27.39%
- Volume
- 357
- Average volume
- 1,386
- Market cap
- 141M+
- 52-week range
- $1.67 – $5.32
- 50-day average
- $4.15
- 200-day average
- $3.01
Performance
| 5D |
1M |
3M |
6M |
| -27.39% |
-62.05% |
-40.36% |
-54.12% |
Price action over the past year
In 251 trading sessions since October 16, 2025, NTLX closed higher on 20 days (8%).
Its best day was April 27, 2026 (+62.50%) and its worst was October 8, 2026 (-47.73%).
The stock moved 10% or more in a single session 27 times.
It opened at least 5% above the previous day's high 13 times.
Recent signals
NTLX news
-
Oct 8, 2026:
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
-
Oct 7, 2026:
SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture
-
Sep 23, 2026:
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations
-
Sep 23, 2026:
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
-
Sep 23, 2026:
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
-
Sep 2, 2026:
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
-
Aug 31, 2026:
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI210 Autism Clinical Trial
-
Aug 31, 2026:
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
About NeuroThera Labs Inc.
Neurothera Labs Inc. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Neurothera's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation, and SCI- 210 for the treatment of ASD and status epilepticus.
Similar stocks
Find more stocks like NTLX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.